<DOC>
	<DOCNO>NCT02745080</DOCNO>
	<brief_summary>The purpose study compare safety efficacy secukinumab monotherapy adalimumab monotherapy patient active psoriatic arthritis naïve biologic therapy intolerant inadequate response conventional DMARDs</brief_summary>
	<brief_title>Efficacy Secukinumab Compared Adalimumab Patients With Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis PsA classify CASPAR ; Rheumatoid factor antiCCP antibody negative ; diagnosis active plaque psoriasis , least one psoriatic plaque ≥2cm diameter nail change consistent psoriasis document history plaque psoriasis ; inadequate control symptom NSAIDs ; inadequate control symptoms conventional DMARD . Pregnant nursing woman , evidence ongoing infectious malignant process ; previous exposure biologic drug Psoriatic Arthritis Psoriasis ; subject take high potency opioid analgesic ; ongoing use prohibit psoriasis treatment / medication ; previous treatment celldepleting therapy include limited antiCD20 , investigational agent . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>secukinumab</keyword>
	<keyword>adalimumab</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>CASPAR</keyword>
</DOC>